Gland Pharma Recommends Final Dividend of ₹20/share, Sets August 11 Record Date
Gland Pharma's Board approved Q4 FY26 results with an unmodified auditor's report. A final dividend of ₹20 per share is recommended for FY26, with August 11, 2026, as the record date. The 48th AGM is scheduled for August 25, 2026.
The declaration of a final dividend and the approval of financial results are material events for the company, impacting shareholder returns and providing financial clarity. The AGM date is also a key upcoming event.
The company announced its financial results and recommended a final dividend, which is generally viewed positively by investors.
Gland Pharma Limited's Board of Directors, in a meeting held on May 15, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026. The company's statutory auditors issued an unmodified audit report on both standalone and consolidated financial statements.
The Board has recommended a final dividend of ₹20 per equity share (2000%) for the financial year 2025-26. This dividend, subject to shareholder approval at the 48th Annual General Meeting (AGM), will be paid within 30 days of the AGM. The record date for determining eligible shareholders for this dividend has been set as Tuesday, August 11, 2026.
Furthermore, the 48th AGM of the company is scheduled to be held through video conferencing (VC) or other audio-visual means (OAVM) on Tuesday, August 25, 2026. The Board meeting commenced at 15:00 IST and concluded at 16:10 IST.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.